ResMedWBO:RMD +1.27%92 Beneish M-Score is -2.60 as of Jun. 24, 2026. GuruFocus rates WBO:RMD with a GF Score™ of 92/100 and a GF Value™ of €238.90 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 765 Medical Devices & Instruments companies, ResMed ranks better than 52.42% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.6 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for ResMed's Beneish M-Score or its related term are showing as below:
WBO:RMD'
s Beneish M-Score Range Over the Past 10 Years
Min: -2.84 Med: -2.4 Max: -1.99
Current: -2.6
During the past 13 years, the highest Beneish M-Score of ResMed was -1.99. The lowest was -2.84. And the median was -2.40.
ResMed Beneish M-Score Related Terms
ResMed Beneish M-Score Historical Data
* Premium members only.
The historical data trend for ResMed's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:RMD vs MDLN, WST, BDX: Beneish M-Score Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where ResMed's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of ResMed for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.019
+
0.528 * 0.954
+
0.404 * 0.9368
+
0.892 * 1.0217
+
0.115 * 0.9068
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.0197
+
4.679 * -0.03671
-
0.327 * 0.9423
=
-2.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(200.664 / (200.664 + 636.346))
/
(226.485 / (226.485 + 630.217))
=
0.239739
/
0.264368
=
0.9068
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(1306.334 - -40.938
-
1626.213)
/
7598.407
=
-0.03671
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
ResMed has a M-score of -2.66 suggests that the company is unlikely to be a manipulator.
ResMed (WBO:RMD) has a Beneish M-Score of -2.60 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ResMed and its competitors. According to the industry distribution chart, ResMed ranks #364 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is ResMed's Beneish M-Score too high?
ResMed's current Beneish M-Score is -2.60. Based on the distribution chart, ResMed ranks #364 out of 765 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ResMed has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Beneish M-Score compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #364 out of 765 companies for Beneish M-Score. This puts ResMed in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on ResMed and its competitors. ResMed's current Beneish M-Score is -2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (WBO:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is €238.90, compared to a current price of €167.55 — trading 29.9% below its estimated fair value. The current Beneish M-Score is -2.60. ResMed's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For ResMed (WBO:RMD), the current Beneish M-Score is -2.60 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (WBO:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of €167.55 is trading 29.9% below its estimated GF Value™ of €238.90.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for WBO:RMD:
Beneish M-Score: -2.60
GF Value™: €238.90 vs. price of €167.55 (29.9% below fair value)
No single metric tells the full story. See the WBO:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
92GF Score
Get the complete analysis for WBO:RMD
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:RMD has been successfully added to your 
